These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25569078)

  • 1. Immune memory to Sudan virus: comparison between two separate disease outbreaks.
    Sobarzo A; Eskira Y; Herbert AS; Kuehne AI; Stonier SW; Ochayon DE; Fedida-Metula S; Balinandi S; Kislev Y; Tali N; Lewis EC; Lutwama JJ; Dye JM; Yavelsky V; Lobel L
    Viruses; 2015 Jan; 7(1):37-51. PubMed ID: 25569078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors.
    Sobarzo A; Stonier SW; Radinsky O; Gelkop S; Kuehne AI; Edri A; Herbert AS; Fedida-Metula S; Lutwama JJ; Yavelsky V; Davis C; Porgador A; Dye JM; Lobel L
    EBioMedicine; 2019 Aug; 46():215-226. PubMed ID: 31326432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus Survivors.
    Sobarzo A; Stonier SW; Herbert AS; Ochayon DE; Kuehne AI; Eskira Y; Fedida-Metula S; Tali N; Lewis EC; Egesa M; Cose S; Lutwama JJ; Yavelsky V; Dye JM; Lobel L
    Viruses; 2016 May; 8(5):. PubMed ID: 27187443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 5. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).
    Sobarzo A; Groseth A; Dolnik O; Becker S; Lutwama JJ; Perelman E; Yavelsky V; Muhammad M; Kuehne AI; Marks RS; Dye JM; Lobel L
    J Infect Dis; 2013 Jul; 208(2):299-309. PubMed ID: 23585686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Sudan Virus Ebola Survivors Maintain Multiple Antiviral Defense Mechanisms.
    Sobarzo A; Moné Y; Lang S; Gelkop S; Brangel P; Kuehne AI; McKendry RA; Mell JC; Ahmed A; Davis C; Dye JM; Lutwama JJ; Lobel L; Veas F; Ehrlich GD
    J Infect Dis; 2024 Aug; 230(2):426-437. PubMed ID: 38066574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.
    Bounds CE; Kwilas SA; Kuehne AI; Brannan JM; Bakken RR; Dye JM; Hooper JW; Dupuy LC; Ellefsen B; Hannaman D; Wu H; Jiao JA; Sullivan EJ; Schmaljohn CS
    PLoS One; 2015; 10(9):e0137786. PubMed ID: 26422247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological evidence of exposure to ebolaviruses in domestic pigs from Guinea.
    Fischer K; Camara A; Troupin C; Fehling SK; Strecker T; Groschup MH; Tordo N; Diederich S
    Transbound Emerg Dis; 2020 Mar; 67(2):724-732. PubMed ID: 31627257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay.
    Sobarzo A; Perelman E; Groseth A; Dolnik O; Becker S; Lutwama JJ; Dye JM; Yavelsky V; Lobel L; Marks RS
    Clin Vaccine Immunol; 2012 Nov; 19(11):1844-52. PubMed ID: 22993411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses.
    Natesan M; Jensen SM; Keasey SL; Kamata T; Kuehne AI; Stonier SW; Lutwama JJ; Lobel L; Dye JM; Ulrich RG
    Clin Vaccine Immunol; 2016 Aug; 23(8):717-24. PubMed ID: 27335383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses.
    Wu F; Zhang S; Zhang Y; Mo R; Yan F; Wang H; Wong G; Chi H; Wang T; Feng N; Gao Y; Xia X; Zhao Y; Yang S
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31947873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors.
    Bramble MS; Hoff N; Gilchuk P; Mukadi P; Lu K; Doshi RH; Steffen I; Nicholson BP; Lipson A; Vashist N; Sinai C; Spencer D; Olinger G; Wemakoy EO; Illunga BK; Pettitt J; Logue J; Marchand J; Varughese J; Bennett RS; Jahrling P; Cavet G; Serafini T; Ollmann Saphire E; Vilain E; Muyembe-Tamfum JJ; Hensely LE; Simmons G; Crowe JE; Rimoin AW
    J Infect Dis; 2018 Nov; 218(12):1929-1936. PubMed ID: 30107445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.
    Flyak AI; Shen X; Murin CD; Turner HL; David JA; Fusco ML; Lampley R; Kose N; Ilinykh PA; Kuzmina N; Branchizio A; King H; Brown L; Bryan C; Davidson E; Doranz BJ; Slaughter JC; Sapparapu G; Klages C; Ksiazek TG; Saphire EO; Ward AB; Bukreyev A; Crowe JE
    Cell; 2016 Jan; 164(3):392-405. PubMed ID: 26806128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.
    Luczkowiak J; Arribas JR; Gómez S; Jiménez-Yuste V; de la Calle F; Viejo A; Delgado R
    Virus Res; 2016 Feb; 213():224-229. PubMed ID: 26739425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques.
    Marzi A; Fletcher P; Feldmann F; Saturday G; Hanley PW; Feldmann H
    Lancet Microbe; 2023 Mar; 4(3):e171-e178. PubMed ID: 36739878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus.
    Macneil A; Reed Z; Rollin PE
    PLoS Negl Trop Dis; 2011 Jun; 5(6):e1175. PubMed ID: 21666792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease.
    Luczkowiak J; Lasala F; Mora-Rillo M; Arribas JR; Delgado R
    J Infect Dis; 2018 Nov; 218(suppl_5):S574-S581. PubMed ID: 29939289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus.
    Ayouba A; Touré A; Butel C; Keita AK; Binetruy F; Sow MS; Foulongne V; Delaporte E; Peeters M
    J Clin Microbiol; 2017 Jan; 55(1):165-176. PubMed ID: 27795350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
    Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE
    Front Immunol; 2021; 12():706757. PubMed ID: 34335620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.